Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vertex Pharmaceuticals Incorporated
< Previous
1
2
3
4
Next >
Vertex to Participate in Upcoming September Investor Conferences
Today 8:00 EDT
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
July 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
July 02, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Second Quarter 2024 Financial Results on August 1
July 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
June 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
June 14, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
June 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming June Investor Conferences
May 22, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Jennifer Schneider Elected to Vertex Board of Directors
May 15, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports First Quarter 2024 Financial Results
May 06, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce First Quarter 2024 Financial Results on May 6
April 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
April 01, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 21, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in Upcoming Investor Conferences
February 20, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
February 13, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Pivotal Trials of Vanzacaftor/Tezacaftor/Deutivacaftor, Next-In-Class Triple Combination Treatment for Cystic Fibrosis
February 05, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
January 30, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5
January 17, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
January 16, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
January 09, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 07, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
December 18, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
December 15, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
December 13, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 11, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
December 08, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex Appoints Nancy Thornberry to its Board of Directors
December 05, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.